<DOC>
	<DOC>NCT01649050</DOC>
	<brief_summary>To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis</brief_summary>
	<brief_title>Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Key Diagnosis of multiple sclerosis (MS) of any type. MS diagnosis at least 6 months prior to screening. Stable MS with no relapse within 3 months prior to screening. Treated or untreated spasticity due to MS for at least 3 months prior to screening, not wholly relieved with antispasticity medications. Key exclusion criteria: Patients with symptoms of spasticity not due to MS. Patients taking three or more different antispasticity medications. Acute MS exacerbation requiring treatment within 3 months of the Screening Visit. Initiation of, or the discontinuation of interferon beta or any other disease modifying therapy for MS within 3 months of the Screening Visit. Use of baclofen pump at any time. Wheelchair or bedbound patients.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Spasticity</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>